SB-258585 is a drug which is used in scientific research. It acts as a potent, selective and orally active
5-HT6receptorantagonist, with a
Ki of 8.9nM.[1] It is used in its
125Iradiolabelled form to map the distribution of 5-HT6 receptors in the brain.[2][3]
^Roberts JC, Reavill C, East SZ, Harrison PJ, Patel S, Routledge C, Leslie RA (April 2002). "The distribution of 5-HT(6) receptors in rat brain: an autoradiographic binding study using the radiolabelled 5-HT(6) receptor antagonist [(125)I]SB-258585". Brain Research. 934 (1): 49–57.
doi:
10.1016/S0006-8993(02)02360-0.
PMID11937069.
S2CID140209933.
^East SZ, Burnet PW, Leslie RA, Roberts JC, Harrison PJ (September 2002). "5-HT6 receptor binding sites in schizophrenia and following antipsychotic drug administration: autoradiographic studies with [125I]SB-258585". Synapse. 45 (3): 191–9.
doi:
10.1002/syn.10097.
PMID12112397.
S2CID25909618.
^Stean TO, Hirst WD, Thomas DR, Price GW, Rogers D, Riley G, et al. (April 2002). "Pharmacological profile of SB-357134: a potent, selective, brain penetrant, and orally active 5-HT(6) receptor antagonist". Pharmacology, Biochemistry, and Behavior. 71 (4): 645–54.
doi:
10.1016/S0091-3057(01)00742-0.
PMID11888556.
S2CID34925312.
^Loiseau F, Dekeyne A, Millan MJ (January 2008). "Pro-cognitive effects of 5-HT6 receptor antagonists in the social recognition procedure in rats: implication of the frontal cortex". Psychopharmacology. 196 (1): 93–104.
doi:
10.1007/s00213-007-0934-5.
PMID17922111.
S2CID35795618.
^Wesołowska A, Nikiforuk A, Stachowicz K (September 2007). "Anxiolytic-like and antidepressant-like effects produced by the selective 5-HT6 receptor antagonist SB-258585 after intrahippocampal administration to rats". Behavioural Pharmacology. 18 (5–6): 439–46.
doi:
10.1097/FBP.0b013e3282d28f9c.
PMID17762512.
S2CID20105974.
SB-258585 is a drug which is used in scientific research. It acts as a potent, selective and orally active
5-HT6receptorantagonist, with a
Ki of 8.9nM.[1] It is used in its
125Iradiolabelled form to map the distribution of 5-HT6 receptors in the brain.[2][3]
^Roberts JC, Reavill C, East SZ, Harrison PJ, Patel S, Routledge C, Leslie RA (April 2002). "The distribution of 5-HT(6) receptors in rat brain: an autoradiographic binding study using the radiolabelled 5-HT(6) receptor antagonist [(125)I]SB-258585". Brain Research. 934 (1): 49–57.
doi:
10.1016/S0006-8993(02)02360-0.
PMID11937069.
S2CID140209933.
^East SZ, Burnet PW, Leslie RA, Roberts JC, Harrison PJ (September 2002). "5-HT6 receptor binding sites in schizophrenia and following antipsychotic drug administration: autoradiographic studies with [125I]SB-258585". Synapse. 45 (3): 191–9.
doi:
10.1002/syn.10097.
PMID12112397.
S2CID25909618.
^Stean TO, Hirst WD, Thomas DR, Price GW, Rogers D, Riley G, et al. (April 2002). "Pharmacological profile of SB-357134: a potent, selective, brain penetrant, and orally active 5-HT(6) receptor antagonist". Pharmacology, Biochemistry, and Behavior. 71 (4): 645–54.
doi:
10.1016/S0091-3057(01)00742-0.
PMID11888556.
S2CID34925312.
^Loiseau F, Dekeyne A, Millan MJ (January 2008). "Pro-cognitive effects of 5-HT6 receptor antagonists in the social recognition procedure in rats: implication of the frontal cortex". Psychopharmacology. 196 (1): 93–104.
doi:
10.1007/s00213-007-0934-5.
PMID17922111.
S2CID35795618.
^Wesołowska A, Nikiforuk A, Stachowicz K (September 2007). "Anxiolytic-like and antidepressant-like effects produced by the selective 5-HT6 receptor antagonist SB-258585 after intrahippocampal administration to rats". Behavioural Pharmacology. 18 (5–6): 439–46.
doi:
10.1097/FBP.0b013e3282d28f9c.
PMID17762512.
S2CID20105974.